MacroGenics(MGNX)

Search documents
MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial – Hagens Berman
GlobeNewswire News Room· 2024-08-22 19:16
SAN FRANCISCO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7, 2024 – May 9, 2024 Lead Plaintiff Deadline: Sept. 24, 2024 Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916-0895 Class Action Lawsuit Against MacroGenics, Inc. (MGNX): A class-action lawsuit has been filed against MacroGenics, a biotechnology company, alleging that it misled in ...
September 24, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MGNX
Prnewswire· 2024-08-22 09:45
NEW YORK, Aug. 22, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=97058&from=4 CLASS PERIOD: March 7, 2024 ...
The Gross Law Firm Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 – MGNX
GlobeNewswire News Room· 2024-08-21 17:18
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=96722&from=3 CLASS PERIOD: March 7, 2 ...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics
Prnewswire· 2024-08-21 14:08
Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MacroGenics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety of its drug vobramitamab duocarmazine, leading to significant investor losses [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $75,000 in MacroGenics between March 7, 2024, and May 9, 2024, to discuss their legal options [1]. - There is a deadline of September 24, 2024, for investors to seek the role of lead plaintiff in a federal securities class action against MacroGenics [2]. - The complaint alleges that MacroGenics and its executives made false or misleading statements and failed to disclose critical safety data from the TAMARACK Phase 2 study [4]. Group 2: Stock Performance Impact - Following the revelation that the drug was significantly more dangerous than previously represented, MacroGenics' stock declined by 77.4%, equating to a drop of $11.36 per share [4]. Group 3: Firm Background and Contact Information - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [3]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding MacroGenics' conduct [6].
Robbins LLP Reminds MacroGenics, Inc. (MGNXX) Investors of the Class Action Lawsuit and Pending Lead Plaintiff Deadline
GlobeNewswire News Room· 2024-08-20 20:47
SAN DIEGO, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired MacroGenics, Inc. (NASDAQ: MGNX) common stock between March 7, 2024 and May 9, 2024. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. For more information, submit a form, email a ...
Kessler Topaz Meltzer & Check, LLP Reminds MGNX Investors of September 24, 2024 Deadline in Securities Fraud Class Action and Urges Investors with Losses to Contact the Firm
Prnewswire· 2024-08-20 14:30
Core Viewpoint - A securities class action lawsuit has been filed against MacroGenics, Inc. for allegedly making false and misleading statements regarding the safety profile of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study [1][2]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of Maryland on behalf of investors who purchased MacroGenics stock or sold puts between March 7, 2024, and May 9, 2024 [1]. - The lead plaintiff deadline for the lawsuit is September 24, 2024 [1][3]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants created a materially misleading impression regarding the safety profile of vobramitamab duocarmazine and the overall data from the Phase 2 TAMARACK study [2]. Group 3: Lead Plaintiff Process - Investors in MacroGenics can seek to be appointed as a lead plaintiff representative of the class by the deadline of September 24, 2024, or may choose to remain an absent class member [3]. - The lead plaintiff will act on behalf of all class members and select counsel to represent the class [3]. Group 4: Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].
Kessler Topaz Meltzer & Check, LLP Encourages MacroGenics, Inc. Investors with Losses to Contact the Firm
GlobeNewswire News Room· 2024-08-17 19:29
RADNOR, Pa., Aug. 17, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTAC ...
MacroGenics, Inc. Class Action: The Gross Law Firm Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX
Prnewswire· 2024-08-15 09:45
Core Viewpoint - MacroGenics, Inc. (NASDAQ: MGNX) is facing a class action lawsuit due to alleged material misrepresentations regarding the safety data of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study, leading to a significant stock decline of 77.4% [1][2]. Group 1 - The class period for the lawsuit is defined as March 7, 2024, to May 9, 2024 [1]. - On May 9, 2024, it was revealed that the drug was significantly more dangerous than previously claimed, resulting in a stock price drop of $11.36 per share [1]. - Shareholders are encouraged to register for the class action and can do so without any cost or obligation [2]. Group 2 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX
GlobeNewswire News Room· 2024-08-15 00:13
NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), of the important September 24, 2024 lead plaintiff deadline. SO WHAT: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...
Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit
Prnewswire· 2024-08-14 13:15
RADNOR, Pa., Aug. 14, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTACT KE ...